Details of the Drug

General Information of Drug (ID: DMUCD9F)

Drug Name
INT131
Synonyms C541917000
Indication
Disease Entry ICD 11 Status REF
Type-2 diabetes 5A11 Phase 2 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C21H12Cl4N2O3S
Canonical SMILES
C1=CC=C2C(=C1)C=C(C=N2)OC3=C(C=C(C=C3Cl)NS(=O)(=O)C4=C(C=C(C=C4)Cl)Cl)Cl
InChI
InChI=1S/C21H12Cl4N2O3S/c22-13-5-6-20(16(23)8-13)31(28,29)27-14-9-17(24)21(18(25)10-14)30-15-7-12-3-1-2-4-19(12)26-11-15/h1-11,27H
InChIKey
NMRWDFUZLLQSBN-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
10229498
ChEBI ID
CHEMBL1236924
CAS Number
315224-26-1
TTD ID
D06QBY
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

References

1 ClinicalTrials.gov (NCT00631007) A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator. U.S. National Institutes of Health.